tiprankstipranks
FMC Corp (FMC)
NYSE:FMC
Want to see FMC full AI Analyst Report?

FMC (FMC) AI Stock Analysis

1,617 Followers

Top Page

FMC

FMC

(NYSE:FMC)

Select Model
Select Model
Select Model
Neutral 45 (OpenAI - 5.2)
Rating:45Neutral
Price Target:
$13.00
▼(-24.29% Downside)
Action:Reiterated
Date:05/20/26
The score is primarily held down by sharply deteriorated financial performance (large losses, higher leverage, and negative operating/free cash flow). Technicals also remain bearish with the stock below key moving averages. Offsetting factors include a very high dividend yield and a mixed but improving operational narrative from the earnings call (Q1 beat, new-actives momentum, Isoflex approval) alongside refinancing/deleveraging actions, though execution and cash-flow risks remain significant.
Positive Factors
New actives momentum
Doubling sales of new active ingredients demonstrates meaningful pipeline commercialization. Over the medium term, stronger adoption of differentiated actives (fluindapyr, Dodhylex) can offset legacy declines, support higher-margin mix, and create recurring revenue as launches scale through 2027.
Negative Factors
High leverage and rising interest expense
Materially higher leverage and elevated interest costs weaken financial resilience. Heavy debt load raises refinancing and covenant risk, limits strategic optionality, and increases sensitivity to earnings volatility, constraining investment and raising the probability of further deleveraging actions.
Read all positive and negative factors
Positive Factors
Negative Factors
New actives momentum
Doubling sales of new active ingredients demonstrates meaningful pipeline commercialization. Over the medium term, stronger adoption of differentiated actives (fluindapyr, Dodhylex) can offset legacy declines, support higher-margin mix, and create recurring revenue as launches scale through 2027.
Read all positive factors

FMC Key Performance Indicators (KPIs)

Any
Any
Revenue by Segment
Revenue by Segment
Breaks down revenue across different business segments, highlighting which areas are driving growth and profitability, and revealing strategic focus or potential vulnerabilities.
Chart InsightsFMC's revenue from Insecticides and Herbicides has seen a notable decline, reflecting ongoing pricing pressures and market challenges. The earnings call highlights a sharp revenue drop, particularly in Latin America due to credit constraints and generic competition. Despite these challenges, the company is seeing strong demand for new active ingredients and improved performance in North America and EMEA. However, strategic cost actions and a significant dividend cut underscore the need to manage cash flow and enhance competitiveness amid these pressures.
Data provided by:The Fly

FMC (FMC) vs. SPDR S&P 500 ETF (SPY)

FMC Business Overview & Revenue Model

Company Description
FMC Corporation, an agricultural sciences company, provides crop protection, plant health, and professional pest and turf management products. It develops, markets, and sells crop protection chemicals that include insecticides, herbicides, and fun...
How the Company Makes Money
FMC primarily makes money by selling branded crop protection products to the agricultural sector. Its revenue model is product-driven: the company generates sales by marketing and distributing formulations (e.g., insecticides, herbicides, fungicid...

FMC Earnings Call Summary

Earnings Call Date:Apr 29, 2026
(Q1-2026)
|
% Change Since: |
Next Earnings Date:Aug 05, 2026
Earnings Call Sentiment Neutral
The call presented a balanced picture: the company beat Q1 guidance, showed meaningful growth in new active ingredients (sales doubled Y/Y), secured regulatory approval for Isoflex in the EU, and has concrete plans and partial line-of-sight to achieve targeted 2026 debt paydown. However, FMC faces material near-term headwinds including lower partner-related revenues, mid-single-digit to double-digit declines in Q2 and full-year EBITDA and EPS, elevated interest expense and leverage, negative Q1 free cash flow, and ongoing cost/tariff uncertainties. Management expects the first half to be an earnings trough with sequential improvement in H2 and stronger results in 2027, but execution risk remains.
Positive Updates
Q1 Sales and Beat vs Guidance
First quarter sales of $762 million were $12 million above the midpoint of guidance. Sales were down 4% year-over-year but up 1% on a like-for-like basis after excluding India.
Negative Updates
Near-Term Revenue and EBITDA Declines
Q2 revenue outlook $850–$900 million (midpoint down ~17% YoY, driven largely by lower sales to diamide partners and removal of India). Q2 adjusted EBITDA guidance $130–$150 million (midpoint down ~32% YoY).
Read all updates
Q1-2026 Updates
Negative
Q1 Sales and Beat vs Guidance
First quarter sales of $762 million were $12 million above the midpoint of guidance. Sales were down 4% year-over-year but up 1% on a like-for-like basis after excluding India.
Read all positive updates
Company Guidance
Management reiterated Q2 revenue guidance of $850–900M (midpoint down ~17% YoY), adjusted EBITDA $130–150M (midpoint down ~32%), and adjusted EPS $0.16–$0.26 (midpoint down ~70%); full‑year 2026 guidance remains sales $3.6–3.8B (midpoint down ~5%), adjusted EBITDA $670–730M (midpoint down ~17%), adjusted EPS $1.63–1.89 (midpoint down ~41%), interest expense $255–275M, D&A $160–170M, adjusted tax rate 16–18%, and free cash flow −$65M to +$65M (breakeven midpoint) including ~$150M of restructuring cash spend. Q1 results beat guidance: sales $762M (+$12M vs midpoint), sales −4% YoY but +1% like‑for‑like ex‑India, FX +5% tailwind, adjusted EBITDA $72M (+$17M vs high end), and adjusted loss/share $(0.23) (+$0.15 vs midpoint). Balance sheet and liquidity metrics include gross debt ~$4.5B, cash $391M, net debt ~$4.1B, gross debt/TTM EBITDA 5.7x, net debt/EBITDA 5.2x, a $2B revolver maturing June 2028 (now fully secured), a secured leverage covenant of 3.5x and a total leverage covenant reinstated at 6.75x on Dec 31, 2026; management is targeting ≈$1B of debt paydown in 2026 with ~70% (~$700M) of proceeds in active negotiation, expects to market a secured high‑yield to redeem $500M of October notes, and noted operational signals supporting H2 (new AI sales doubled YoY in Q1, orders representing 32% of H2 Brazil direct sales by end‑April and ~50% expected by end‑June).

FMC Financial Statement Overview

Summary
Financial quality has weakened sharply: revenue collapsed into the latest periods, profitability swung to large losses, leverage rose meaningfully (debt-to-equity near ~2.0x), and operating/free cash flow turned negative in 2025 and TTM—reducing flexibility and increasing near-term risk.
Income Statement
18
Very Negative
Balance Sheet
34
Negative
Cash Flow
26
Negative
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue3.43B3.47B4.25B4.49B5.80B5.05B
Gross Profit1.21B1.28B1.58B1.91B2.39B2.19B
EBITDA-222.50M-84.70M737.40M786.20M1.30B1.19B
Net Income-2.50B-2.24B339.90M1.32B736.50M739.60M
Balance Sheet
Total Assets9.42B9.69B11.65B11.93B11.17B10.67B
Cash, Cash Equivalents and Short-Term Investments390.90M584.50M357.30M302.40M572.00M516.80M
Total Debt4.66B4.20B3.50B4.11B3.42B3.34B
Total Liabilities7.57B7.59B7.14B7.49B7.77B7.53B
Stockholders Equity1.82B2.07B4.49B4.41B3.38B3.12B
Cash Flow
Free Cash Flow-123.50M-176.50M603.20M-520.30M440.10M720.00M
Operating Cash Flow-138.50M-80.20M671.10M-386.40M582.40M820.10M
Investing Cash Flow-77.90M-108.30M263.60M-154.40M-266.40M-112.00M
Financing Cash Flow276.20M394.60M-870.10M331.50M-237.40M-747.90M

FMC Technical Analysis

Technical Analysis Sentiment
Negative
Last Price17.17
Price Trends
50DMA
15.27
Negative
100DMA
15.03
Negative
200DMA
20.74
Negative
Market Momentum
MACD
-0.66
Positive
RSI
41.65
Neutral
STOCH
44.18
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FMC, the sentiment is Negative. The current price of 17.17 is above the 20-day moving average (MA) of 14.36, above the 50-day MA of 15.27, and below the 200-day MA of 20.74, indicating a bearish trend. The MACD of -0.66 indicates Positive momentum. The RSI at 41.65 is Neutral, neither overbought nor oversold. The STOCH value of 44.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FMC.

FMC Risk Analysis

FMC disclosed 48 risk factors in its most recent earnings report. FMC reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

FMC Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
75
Outperform
$19.24B8.1435.17%2.56%20.85%46.79%
66
Neutral
$3.29B3.69-33.72%4.52%-1.89%216.52%
62
Neutral
$8.27B13.274.32%3.36%7.80%-32.94%
61
Neutral
$10.43B7.12-0.05%2.87%2.86%-36.73%
52
Neutral
$6.92B-7.865.92%3.70%12.34%-87.77%
46
Neutral
$213.48M-1.47-0.45%88.87%
45
Neutral
$1.77B-1.92-83.04%16.68%-16.63%-865.93%
* Basic Materials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
FMC
FMC
13.55
-25.38
-65.19%
CF
Cf Industries Holdings
125.22
39.15
45.48%
MOS
Mosaic Co
21.41
-13.06
-37.88%
SMG
Scotts Miracle-Gro Company
57.53
-2.63
-4.38%
ICL
Icl
6.42
0.05
0.80%
USBC
USBC
0.44
-0.06
-11.60%

FMC Corporate Events

Business Operations and StrategyPrivate Placements and Financing
FMC Plans $750 Million Senior Secured Notes Offering
Positive
May 19, 2026
On May 19, 2026, FMC Corporation announced plans to issue $750 million of senior secured notes due 2031 in a private offering to qualified institutional buyers and certain non-U.S. investors. The notes will be guaranteed by key subsidiaries and se...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
FMC Shareholders Weigh Governance Changes at 2026 Annual Meeting
Neutral
Apr 29, 2026
FMC held its 2026 annual shareholders’ meeting on April 28, 2026, with approximately 85% of outstanding shares represented in person or by proxy. Shareholders elected nine directors, each to serve a one-year term expiring in 2027, underscori...
Business Operations and StrategyPrivate Placements and Financing
FMC Amends Syndicated Credit Agreement, Enhancing Creditor Protections
Neutral
Apr 20, 2026
On April 16, 2026, FMC Corporation and certain subsidiaries executed a sixth amendment to their existing syndicated credit agreement, adjusting the maximum leverage ratio and minimum interest coverage ratio for specific quarters and setting a new ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 20, 2026